Theravance submits NDA for hospital-acquired pneumonia drug

01/27/2009 | RTT News

Theravance has submitted a New Drug Application to the FDA for telavancin, its drug candidate for hospital-acquired pneumonia caused by Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus. "The submission of the telavancin NDA for HAP is another important milestone for the telavancin program," CEO Rick Winningham said.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN